查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1802041

再生醫療的全球市場:各產品類型，各材料，各基因改造材料，各用途，各終端用戶，各地區，市場規模，產業趨勢，機會分析與預測(2025年～2033年)

Global Regenerative Medicine Market: Product Type, Material, Genetically Engineered Material, Application, End Users, Region Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 300 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

再生醫學市場正在經歷顯著擴張，一些預測顯示，未來十年其全球估值將大幅上升。 2024 年，市場規模約為 730.1 億美元，預計到 2033 年將飆升至 5,785.9 億美元。 2025 年至 2033 年，此成長的複合年增長率為 25.86%。這一驚人成長主要得益於幹細胞療法、基因編輯和組織工程等關鍵技術的重大進步。

然而，市場成長受制於顯著的地區差異，這會影響投資速度和患者獲得治療的機會。北美仍處於領先地位，受益於其最發達的再生療法臨床基礎設施。到2024年中期，約有400家專業機構將獲得自體細胞治療認證，這將證明該地區在提供個人化再生醫學方面的先進能力。此外，美國已有八個州頒布立法，強制推行基於價值的合同，這有助於減輕這些創新療法高昂的前期成本帶來的財務負擔。此類監管和臨床框架支持可持續的採用和報銷模式，使更廣泛的患者能夠獲得治療。

值得關注的市場發展

再生醫學市場的競爭格局由老牌生物製藥巨頭主導，他們利用尖端技術推動創新並擴大全球影響力。美敦力公司是該領域的領導者，業務遍及150多個國家，約有9萬名專業人員。廣泛的全球影響力使美敦力能夠利用多元化的市場和專業知識，並始終站在再生醫學發展的前沿。

其他影響市場的關鍵參與者包括艾伯維公司 (AbbVie Inc.)、安進公司 (Amgen Inc.) 和諾華製藥公司 (Novartis Pharma AG)，它們均在研發方面投入大量資金。這些公司不斷突破再生醫學的界限，推動突破性進展，以應對各種疾病。他們對研發的投入推動了一系列創新，並確保了持續不斷的新型療法，從而改善病患照護。

核心推動因素

再生醫學市場目前正經歷前所未有的監管審批激增，這些發展正在從根本上改變全球數百萬患者的治療途徑。到2024年，主要國際市場的監管機構都將加快審批流程，以跟上再生療法的快速發展。美國食品藥物管理局 (FDA) 尤其發揮關鍵作用，光是今年前三個季度，就已將突破性療法認定授予了超過15種新型細胞和基因療法。

同樣，日本醫藥品醫療器材綜合機構 (PMDA) 也繼續以其漸進式有條件審批框架樹立全球標準。這種監管方式允許再生醫學產品在安全性和有效性得到證明後，即使仍在收集全面的療效數據，也能提前進入市場。這項政策不僅鼓勵創新，也有助於患者快速獲得可能改變人生的療法。

新機會中的趨勢

人工智慧 (AI) 與再生醫學的融合，利用前所未有的計算能力，從根本上改變了治療開發時間表和患者預後。這種融合涵蓋了整個再生醫學價值鏈，從最初的發現和研究到製造優化和持續的患者監測。人工智慧能夠快速且準確地分析大量資料集，從而加速識別新的治療靶點，優化複雜的製造流程，並實現即時、個人化的患者護理。

人工智慧在再生醫學領域的實際應用展現了其對臨床實踐的變革性影響。例如，麻省總醫院實施了一套由人工智慧驅動的監測系統，持續追蹤3500名接受幹細胞治療的患者的健康狀況。此創新系統可在臨床症狀出現前72小時內檢測到移植排斥的早期跡象，從而能夠及時幹預，顯著改善患者的預後。

優化障礙

製造課題是擴大再生醫學市場的最大障礙，儘管獲準的療法數量不斷增加，但這仍然嚴重限制了患者的可及性。先進的細胞和基因療法的生產非常複雜，需要專門的設施並嚴格遵守良好生產規範 (GMP)，每條生產線的資本投入超過2.5億美元。除了這些初始成本外，每位患者的治療費用約為8.5萬美元，而且營運成本仍然很高。

這些資金和技術障礙對擴大生產以滿足激增的需求構成了重大瓶頸。其中最顯著的阻礙因素之一在於病毒載體的生產，而病毒載體是許多基因療法的重要組成部分。目前，全球產能每年僅能滿足約3.5萬例患者的需求。與預期的18萬例治療需求相比，這數字遠遠不足。這種短缺對及時為患者提供改變命運的治療方案構成了重大障礙。

詳細的市場區隔

按產品類型劃分，幹細胞療法將繼續主導全球再生醫學市場，在2024年至2025年期間佔34.64%的顯著佔有率。這一強勁的市場地位得益於突破性的臨床應用以及幹細胞技術提供的治療能力的持續擴展。在這些進步中，誘導多能幹細胞 (iPSC) 技術脫穎而出，成為一項突破性進展，顯著擴展了幹細胞治療的範圍和有效性。 iPSC 是將成體細胞重新編程為胚胎狀態，從而能夠生成各種特化細胞，為治療複雜疾病提供了前所未有的可能性。

按材料類型劃分，生物衍生材料在再生醫學市場佔主導地位，在 2024 年至 2025 年期間佔了高達 54.77% 的市場佔有率，預計複合年增長率 (CAGR) 最高可達 26.30%。這種領先地位源於生物材料無與倫比的生物相容性和治療功效，使其成為各種再生應用的首選。該領域的主導地位在細胞外基質 (ECM) 技術的突破性進展中尤為明顯。 ECM 為組織修復和再生提供必要的支架和生物活性訊號。

從應用角度來看，腫瘤學繼續在再生醫學市場佔主導地位，預計在2024年至2025年期間將佔49.22%的市場佔有率。這種主導地位主要歸功於CAR-T細胞療法和其他創新癌症療法等突破性進展，這些療法顯著改善了患者的預後。這些突破代表了血液系統惡性腫瘤和某些實體腫瘤治療的範式轉變，為此前治療選擇有限的患者帶來了新的希望。

從最終用戶角度來看，醫院和診所已牢固確立了其在再生醫學市場中的主導地位，在2024年至2025年期間佔了43.57%的顯著市場佔有率。這一令人印象深刻的地位得益於26.37%的強勁複合年增長率，突顯了再生醫學在這些醫療環境中的快速擴張和日益普及。作為先進再生療法的主要交付中心，醫院和診所正在全球進行大量基礎設施投資，總額超過 85 億美元。

各市場區隔明細

各產品類型

  • 基因治療
  • 細胞療法
  • 幹細胞療法
    • 自體療法
    • 同類療法
  • 組織工程
  • 低分子·生技藥品
  • 其他

各材料

  • 合成材料
    • 生物分解性合成聚合物
    • 鷹架
    • 人工血管移植
    • 水凝膠材料
    • 其他
  • 生物來源材料
    • 膠原蛋白
    • 異種材料
    • 其他
  • 基因重組材料
    • 遺傳基因操作細胞
    • 基因轉殖
    • 纖維母細胞
    • 神經幹細胞
    • 遺傳基因活性化矩陣
    • 其他
  • 醫藥品
    • 生技藥品
    • 低分子醫藥品
    • 其他

各用途

  • 皮膚科學
  • 肌肉骨骼系統
  • 免疫·發炎
  • 腫瘤學
  • 心臟血管
  • 神經學
  • 眼科
  • 其他

各終端用戶

  • 醫院·診所
  • 專門中心
  • 政府·學術研究機關
  • 其他

各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 波蘭
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲·紐西蘭
    • ASEAN
      • 馬來西亞
      • 新加坡
      • 泰國
      • 印尼
      • 菲律賓
      • 越南
      • 其他
    • 其他地區
  • 中東·非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 其他

市場參與企業

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • U.S. Stem Cell, Inc.
  • 其他的主要企業

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理:全球再生醫療市場

第4章 全球再生醫療市場概要

  • 產業價值鏈分析
    • 材料供應商
    • 廠商
    • 批發商
    • 終端用戶
  • 再生醫療的供應鏈
    • 細胞的採購與收集
    • 品管與試驗
    • 製造及加工
    • 臨床試驗與法規當局的認證
    • 患者管理
    • 上市後監測
  • 產業展望
  • 大環境分析
  • 波特的五力分析
  • 市場動態和趨勢
  • COVID-19對市場成長趨勢的影響評估
  • 市場成長與展望
  • 競爭儀表板

第5章 全球再生醫療市場分析(各產品類型)

  • 重要的洞察
  • 市場規模與預測，2020年～2033年(10億美元)
    • 基因治療
    • 細胞療法
    • 幹細胞療法
    • 組織工程
    • 低分子化合物及生技藥品
    • 其他

第6章 全球再生醫療市場分析(各材料)

  • 重要的洞察
  • 市場規模與預測，2020年～2033年(10億美元)
    • 合成材料
    • 生物來源材料
    • 基因改造材料
    • 醫藥品

第7章 全球再生醫療市場分析(各用途)

  • 重要的洞察
  • 市場規模與預測，2020年～2033年(10億美元)
    • 皮膚科
    • 肌肉骨骼
    • 免疫學和發炎
    • 腫瘤學
    • 心血管系統
    • 神經學
    • 眼科
    • 其他

第8章 全球再生醫療市場分析(各終端用戶)

  • 重要的洞察
  • 市場規模與預測，2020年～2033年(10億美元)
    • 醫院和診療所
    • 專門中心
    • 政府及學術調查機關
    • 其他

第9章 全球再生醫療市場分析(各地區)

  • 重要的洞察
  • 市場規模與預測，2020年～2033年(10億美元)
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第10章 北美的再生醫療市場分析

第11章 美國的再生醫療市場分析

第12章 加拿大的再生醫療市場分析

第13章 墨西哥的再生醫療市場分析

第14章 歐洲的再生醫療市場分析

第15章 英國的再生醫療16.1.重要的洞察

第16章 德國的再生醫療市場分析

第17章 法國的再生醫療市場分析

第18章 義大利的再生醫療市場分析

第19章 西班牙的再生醫療市場分析

第20章 波蘭的再生醫療市場分析

第21章 俄羅斯的再生醫療市場分析

第22章 其他的歐洲的再生醫療市場分析

第23章 亞太地區的再生醫療市場分析

第24章 中國的再生醫療市場分析

第25章 印度的再生醫療市場分析

第26章 日本的再生醫療市場分析

第27章 韓國的再生醫療市場分析

第28章 澳洲和紐西蘭的再生醫療市場分析

第29章 ASEAN的再生醫療市場分析

第30章 其他的亞太地區的再生醫療市場分析

第31章 中東·非洲的再生醫療市場分析

第32章 UAE的再生醫療市場分析

第33章 沙烏地阿拉伯的再生醫療市場分析

第34章 南非的再生醫療市場分析

第35章 其他的中東·非洲的再生醫療市場分析

第36章 南美的再生醫療市場分析

第37章 阿根廷的再生醫療市場分析

第38章 巴西的再生醫療市場分析

第39章 其他的南美的再生醫療市場分析

第40章 企業簡介

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • US Stem Cell, Inc.
  • Other Prominent Players
簡介目錄
Product Code: AA1023640

The regenerative medicine market is undergoing remarkable expansion, with projections indicating a dramatic rise in its global valuation over the coming decade. In 2024, the market was valued at approximately US$ 73.01 billion, and this figure is expected to surge to an estimated US$ 578.59 billion by 2033. This growth corresponds to a robust compound annual growth rate (CAGR) of 25.86% during the forecast period from 2025 to 2033. Such an impressive trajectory is primarily driven by significant advancements in key technologies like stem cell therapy, gene editing, and tissue engineering.

The market's growth, however, is characterized by notable regional disparities that influence the pace of investment and patient access to therapies. North America remains at the forefront, benefiting from the most developed clinical infrastructure for regenerative treatments. By mid-2024, approximately 400 specialized centers had received certification to administer autologous cell therapies, underscoring the region's advanced capabilities in delivering personalized regenerative care. Furthermore, eight U.S. states had enacted legislation mandating value-based agreements, which help mitigate the financial burden of high upfront costs associated with these innovative treatments. This regulatory and clinical framework supports sustainable adoption and reimbursement models, enabling broader patient access.

Noteworthy Market Developments

The competitive landscape of the regenerative medicine market is dominated by well-established biopharmaceutical giants who are harnessing cutting-edge technologies to drive innovation and expand their global reach. Medtronic Plc stands out as a leader, with operations spanning over 150 countries and a workforce of approximately 90,000 professionals. This extensive global presence enables Medtronic to leverage diverse markets and expertise, positioning the company at the forefront of regenerative medicine advancements.

Other major players shaping the market include AbbVie Inc., Amgen Inc., and Novartis Pharma AG, each distinguished by their substantial investments in research and development. These companies continuously push the boundaries of regenerative therapies, driving breakthroughs that address a wide range of medical conditions. Their commitment to R&D fuels innovation pipelines, ensuring a steady flow of novel treatments that enhance patient care.

Core Growth Drivers

The regenerative medicine market is currently experiencing an unprecedented surge in regulatory approvals, a development that is fundamentally reshaping therapeutic accessibility for millions of patients around the globe. Throughout 2024, regulatory agencies across key international markets have accelerated their approval processes to keep pace with the rapid advancements in regenerative therapies. In particular, the U.S. Food and Drug Administration (FDA) has played a pivotal role by granting breakthrough therapy designations to more than 15 novel cell and gene therapies within just the first three quarters of the year.

Similarly, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) continues to set a global standard with its progressive conditional approval framework. This regulatory approach allows regenerative medicine products to enter the market early once they have demonstrated safety and a probable benefit, even if comprehensive efficacy data is still being collected. This policy not only encourages innovation but also facilitates faster patient access to potentially life-changing treatments.

Emerging Opportunity Trends

The convergence of artificial intelligence (AI) with regenerative medicine is fundamentally transforming therapeutic development timelines and patient outcomes by leveraging unprecedented computational power. This integration spans the entire regenerative medicine value chain, from initial discovery and research to manufacturing optimization and ongoing patient monitoring. AI's ability to analyze vast datasets rapidly and accurately is accelerating the identification of novel therapeutic targets, optimizing complex manufacturing processes, and enabling real-time, personalized patient care.

Real-world applications of AI within regenerative medicine illustrate its transformative impact on clinical practice. For instance, Massachusetts General Hospital has implemented an AI-driven monitoring system that continuously tracks the health status of 3,500 patients undergoing stem cell therapy. This innovative system is capable of detecting early signs of transplant rejection up to 72 hours before symptoms become clinically apparent, allowing for timely interventions that significantly improve patient outcomes.

Barriers to Optimization

Manufacturing challenges represent the most formidable obstacle to the expansion of the regenerative medicine market, significantly limiting patient access despite a growing number of therapeutic approvals. The complexity of producing advanced cell and gene therapies demands specialized facilities that comply with stringent Good Manufacturing Practice (GMP) standards, requiring capital investments exceeding US$ 250 million for each production line. In addition to these upfront costs, operational expenses remain exceptionally high, with treatment costs reaching approximately US$ 85,000 per patient.

These financial and technical barriers create significant bottlenecks in scaling production to meet the rapidly increasing demand. One of the most critical constraints lies in the production of viral vectors, which are essential components for many gene therapies. Currently, global manufacturing capacity can only accommodate around 35,000 patient doses annually, a figure vastly insufficient compared to the estimated demand of 180,000 treatments. This shortfall presents a major hurdle in delivering life-changing therapies to patients in a timely manner.

Detailed Market Segmentation

By Product Type, stem cell therapy continues to hold a dominant position in the global regenerative medicine market, capturing a significant 34.64% share during the 2024-2025 period. This strong market presence is fueled by groundbreaking clinical applications and the ongoing expansion of therapeutic capabilities that stem cell technologies offer. Among these advances, induced pluripotent stem cell (iPSC) technology stands out as a revolutionary development that has significantly broadened the scope and effectiveness of stem cell therapies. iPSCs, which are adult cells reprogrammed to an embryonic-like state, enable the generation of a wide variety of specialized cell types, offering unprecedented potential for treating complex diseases.

By Material, biologically derived materials hold a dominant position in the regenerative medicine market, commanding an impressive 54.77% share during 2024-2025 and projecting the highest compound annual growth rate (CAGR) of 26.30%. This leadership is rooted in the unparalleled biocompatibility and therapeutic efficacy that biologically sourced materials offer, making them the preferred choice for a wide range of regenerative applications. The segment's prominence is particularly evident in the groundbreaking advancements in extracellular matrix (ECM) technologies, which provide essential scaffolding and bioactive cues to support tissue repair and regeneration.

By Application, the oncology segment continues to hold a commanding position in the regenerative medicine market, capturing a substantial 49.22% share during the 2024-2025 period. This dominance is largely driven by revolutionary advancements such as CAR-T cell therapies and other innovative cancer treatment modalities that are dramatically improving patient outcomes. These breakthroughs represent a paradigm shift in how hematological malignancies and certain solid tumors are treated, offering new hope to patients who previously had limited options.

By End Users, hospitals and clinics have firmly established themselves as the dominant end users in the regenerative medicine market, commanding a significant market share of 43.57% during 2024-2025. This impressive position is underpinned by a robust compound annual growth rate (CAGR) of 26.37%, highlighting the rapid expansion and increasing adoption of regenerative medicine within these healthcare settings. As primary delivery centers for advanced regenerative therapies, hospitals and clinics have been making substantial infrastructure investments worldwide, totaling over US$ 8.5 billion.

Segment Breakdown

By Product Type

  • Gene Therapy
  • Cell Therapy
  • Stem Cell Therapy
    • Autologous Therapy
    • Allogenic Therapy
  • Tissue-Engineering
  • Small Molecules & Biologics
  • Others

By Material

  • Synthetic material
    • Biodegradable synthetic polymers
    • Scaffold
    • Artificial Vascular Graft
    • Hydrogel Material
    • Others
  • Biologically derived material
    • Collagen
    • Xenogeneic material
    • Others
  • Genetically Engineered Material
    • Genetically Manipulated Cell
    • Transgenics
    • Fibroblast
    • Neural Stem Cell
    • Gene-Activated Matrices
    • Others
  • Pharmaceutical
    • Biologics
    • Small Molecules
    • Others

By Application

  • Dermatology
  • Musculoskeletal
  • Immunology & Inflammation
  • Oncology
  • Cardiovascular
  • Neurology
  • Ophthalmology
  • Others

By End User

  • Hospitals & Clinics
  • Speciality Centers
  • Government & Academic Research Institutes
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Poland
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • ASEAN
      • Malaysia
      • Singapore
      • Thailand
      • Indonesia
      • Philippines
      • Vietnam
      • Rest of ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Leading Market Participants

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • U.S. Stem Cell, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Regenerative Medicine Market

Chapter 4. Global Regenerative Medicine Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Supply chain of regenerative medicine
    • 4.2.1. Cell Sourcing and Collection
    • 4.2.2. Quality Control and Testing
    • 4.2.3. Manufacturing and Processing
    • 4.2.4. Clinical Trials and Regulatory Approval
    • 4.2.5. Patient Administration
    • 4.2.6. Post-Market Surveillance
  • 4.3. Industry Outlook
    • 4.3.1. Advances in Regenerative Medicine and Tissue Engineering
    • 4.3.2. Regulation of Regenerative Medicine in Japan
    • 4.3.3. Dissemination of Regenerative Medicine in Japan
    • 4.3.4. Overview: Japan Strengthens Regenerative Medicine Oversight
    • 4.3.5. Regenerative Medicine at a Global Level: Current Patterns and Global Trends
    • 4.3.6. Comparative lessons in regenerative medicine readiness: UK and Japan Case Study
    • 4.3.7. A comparative analysis of attitudes toward stem cell research and regenerative medicine between six countries (Japan, South Korea, the USA, the UK, Germany, and France)
  • 4.4. PESTLE Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Market Dynamics and Trends
    • 4.6.1. Growth Drivers
    • 4.6.2. Restraints
    • 4.6.3. Challenges
    • 4.6.4. Key Trend
  • 4.7. Covid-19 Impact Assessment on Market Growth Trend
  • 4.8. Market Growth and Outlook
    • 4.8.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2033
    • 4.8.2. Price Trend Analysis, By Product Type
  • 4.9. Competition Dashboard
    • 4.9.1. Market Concentration Rate
    • 4.9.2. Company Market Share Analysis (Value %), 2024
    • 4.9.3. Competitor Mapping

Chapter 5. Global Regenerative Medicine Market Analysis, By Product Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 5.2.1. Gene Therapy
    • 5.2.2. Cell Therapy
    • 5.2.3. Stem Cell Therapy
      • 5.2.3.1. Autologous Therapy
      • 5.2.3.2. Allogenic Therapy
    • 5.2.4. Tissue-Engineering
    • 5.2.5. Small Molecules & Biologics
    • 5.2.6. Others

Chapter 6. Global Regenerative Medicine Market Analysis, By Material

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 6.2.1. Synthetic material
      • 6.2.1.1. Biodegradable synthetic polymers
      • 6.2.1.2. Scaffold
      • 6.2.1.3. Artificial Vascular Graft
      • 6.2.1.4. Hydrogel Material
      • 6.2.1.5. Others
    • 6.2.2. Biologically derived material
      • 6.2.2.1. Collagen
      • 6.2.2.2. Xenogeneic material
      • 6.2.2.3. Others
    • 6.2.3. Genetically Engineered Material
      • 6.2.3.1. Genetically Manipulated Cell
      • 6.2.3.2. Transgenics
      • 6.2.3.3. Fibroblast
      • 6.2.3.4. Neural Stem Cell
      • 6.2.3.5. Gene-Activated Matrices
      • 6.2.3.6. Others
    • 6.2.4. Pharmaceutical
      • 6.2.4.1. Biologics
      • 6.2.4.2. Small Molecules
      • 6.2.4.3. Others

Chapter 7. Global Regenerative Medicine Market Analysis, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 7.2.1. Dermatology
    • 7.2.2. Musculoskeletal
    • 7.2.3. Immunology & Inflammation
    • 7.2.4. Oncology
    • 7.2.5. Cardiovascular
    • 7.2.6. Neurology
    • 7.2.7. Ophthalmology
    • 7.2.8. Others

Chapter 8. Global Regenerative Medicine Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Speciality Centers
    • 8.2.3. Government & Academic Research Institutes
    • 8.2.4. Others

Chapter 9. Global Regenerative Medicine Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Poland
        • 9.2.2.1.7. Russia
        • 9.2.2.1.8. Rest of Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Regenerative Medicine Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 10.2.1. By Product Type
    • 10.2.2. By Material
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. The U.S. Regenerative Medicine Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 11.2.1. By Product Type
    • 11.2.2. By Material
    • 11.2.3. By Application
    • 11.2.4. By End User

Chapter 12. Canada Regenerative Medicine Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 12.2.1. By Product Type
    • 12.2.2. By Material
    • 12.2.3. By Application
    • 12.2.4. By End User

Chapter 13. Mexico Regenerative Medicine Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 13.2.1. By Product Type
    • 13.2.2. By Material
    • 13.2.3. By Application
    • 13.2.4. By End User

Chapter 14. Europe Regenerative Medicine Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 14.2.1. By Product Type
    • 14.2.2. By Material
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. The UK Regenerative Medicine 16.1. Key Insights

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 15.2.1. By Product Type
    • 15.2.2. By Material
    • 15.2.3. By Application
    • 15.2.4. By End User

Chapter 16. Germany Regenerative Medicine Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 16.2.1. By Product Type
    • 16.2.2. By Material
    • 16.2.3. By Application
    • 16.2.4. By End User

Chapter 17. France Regenerative Medicine Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 17.2.1. By Product Type
    • 17.2.2. By Material
    • 17.2.3. By Application
    • 17.2.4. By End User

Chapter 18. Italy Regenerative Medicine Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 18.2.1. By Product Type
    • 18.2.2. By Material
    • 18.2.3. By Application
    • 18.2.4. By End User

Chapter 19. Spain Regenerative Medicine Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 19.2.1. By Product Type
    • 19.2.2. By Material
    • 19.2.3. By Application
    • 19.2.4. By End User

Chapter 20. Poland Regenerative Medicine Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 20.2.1. By Product Type
    • 20.2.2. By Material
    • 20.2.3. By Application
    • 20.2.4. By End User

Chapter 21. Russia Regenerative Medicine Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 21.2.1. By Product Type
    • 21.2.2. By Material
    • 21.2.3. By Application
    • 21.2.4. By End User

Chapter 22. Rest of Europe Regenerative Medicine Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 22.2.1. By Product Type
    • 22.2.2. By Material
    • 22.2.3. By Application
    • 22.2.4. By End User

Chapter 23. Asia Pacific Regenerative Medicine Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 23.2.1. By Product Type
    • 23.2.2. By Material
    • 23.2.3. By Application
    • 23.2.4. By End User
    • 23.2.5. By Country

Chapter 24. China Regenerative Medicine Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 24.2.1. By Product Type
    • 24.2.2. By Material
    • 24.2.3. By Application
    • 24.2.4. By End User

Chapter 25. India Regenerative Medicine Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 25.2.1. By Product Type
    • 25.2.2. By Material
    • 25.2.3. By Application
    • 25.2.4. By End User

Chapter 26. Japan Regenerative Medicine Market Analysis

  • 26.1. Key Insights
  • 26.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 26.2.1. By Product Type
    • 26.2.2. By Material
    • 26.2.3. By Application
    • 26.2.4. By End User

Chapter 27. South Korea Regenerative Medicine Market Analysis

  • 27.1. Key Insights
  • 27.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 27.2.1. By Product Type
    • 27.2.2. By Material
    • 27.2.3. By Application
    • 27.2.4. By End User

Chapter 28. Australia & New Zealand Regenerative Medicine Market Analysis

  • 28.1. Key Insights
  • 28.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 28.2.1. By Product Type
    • 28.2.2. By Material
    • 28.2.3. By Application
    • 28.2.4. By End User

Chapter 29. ASEAN Regenerative Medicine Market Analysis

  • 29.1. Key Insights
  • 29.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 29.2.1. By Product Type
    • 29.2.2. By Material
    • 29.2.3. By Application
    • 29.2.4. By End User

Chapter 30. Rest of Asia Pacific Regenerative Medicine Market Analysis

  • 30.1. Key Insights
  • 30.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 30.2.1. By Product Type
    • 30.2.2. By Material
    • 30.2.3. By Application
    • 30.2.4. By End User

Chapter 31. Middle East and Africa Regenerative Medicine Market Analysis

  • 31.1. Key Insights
  • 31.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 31.2.1. By Product Type
    • 31.2.2. By Material
    • 31.2.3. By Application
    • 31.2.4. By End User
    • 31.2.5. By Country

Chapter 32. UAE Regenerative Medicine Market Analysis

  • 32.1. Key Insights
  • 32.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 32.2.1. By Product Type
    • 32.2.2. By Material
    • 32.2.3. By Application
    • 32.2.4. By End User

Chapter 33. Saudi Arabia Regenerative Medicine Market Analysis

  • 33.1. Key Insights
  • 33.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 33.2.1. By Product Type
    • 33.2.2. By Material
    • 33.2.3. By Application
    • 33.2.4. By End User

Chapter 34. South Africa Regenerative Medicine Market Analysis

  • 34.1. Key Insights
  • 34.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 34.2.1. By Product Type
    • 34.2.2. By Material
    • 34.2.3. By Application
    • 34.2.4. By End User

Chapter 35. Rest of MEA Regenerative Medicine Market Analysis

  • 35.1. Key Insights
  • 35.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 35.2.1. By Product Type
    • 35.2.2. By Material
    • 35.2.3. By Application
    • 35.2.4. By End User

Chapter 36. South America Regenerative Medicine Market Analysis

  • 36.1. Key Insights
  • 36.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 36.2.1. By Product Type
    • 36.2.2. By Material
    • 36.2.3. By Application
    • 36.2.4. By End User
    • 36.2.5. By Country

Chapter 37. Argentina Regenerative Medicine Market Analysis

  • 37.1. Key Insights
  • 37.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 37.2.1. By Product Type
    • 37.2.2. By Material
    • 37.2.3. By Application
    • 37.2.4. By End User

Chapter 38. Brazil Regenerative Medicine Market Analysis

  • 38.1. Key Insights
  • 38.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 38.2.1. By Product Type
    • 38.2.2. By Material
    • 38.2.3. By Application
    • 38.2.4. By End User

Chapter 39. Rest of South America Regenerative Medicine Market Analysis

  • 39.1. Key Insights
  • 39.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 39.2.1. By Product Type
    • 39.2.2. By Material
    • 39.2.3. By Application
    • 39.2.4. By End User

Chapter 40. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 40.1. Allergan PLC
  • 40.2. Baxter International Inc
  • 40.3. Bayer AG
  • 40.4. Boehringer Ingelheim
  • 40.5. Cesca Therapeutics, Inc.
  • 40.6. F. Hoffmann-La Roche Ltd.
  • 40.7. Fujifilm Corporation
  • 40.8. Medtronic plc
  • 40.9. Merck KGaA
  • 40.10. Mimedx Group Inc
  • 40.11. Novartis AG
  • 40.12. Organogenesis, Inc.
  • 40.13. Osiris Therapeutics
  • 40.14. Pfizer, Inc.
  • 40.15. Takara Bio Inc.
  • 40.16. U.S. Stem Cell, Inc.
  • 40.17. Other Prominent Players